ALDX
Aldeyra Therapeutics, Inc.
$1.52
-1.61%
$93.5M
No data for this timeframe.
Vol
Market Cap$93.5M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (83%)
Inst. Holders8 funds
Inst. Value$30.7M
Inst. Activity1 buys / 1 sells
Insider Activity2B / 0S
Insider Net $$105.1K
Reddit Sentiment63° Warm
SEC Reports3
Recent Activity
Apr 27, 2026
SEC
Aldeyra Therapeutics filed additional definitive proxy materials for its 2026 Annual Meeting of Stockholders, scheduled
DEFA14A — Impact 2/10
Apr 24, 2026
short_volume
Short Volume: ALDX — 55.3% short (0.4M / 0.8M)
Short: 419,988 | Exempt: 4,000 | TRF Vol: 759,958 | Short Ratio: 55.3% | Off-exchange volume (dark p
Apr 20, 2026
SEC
Martin J. Joyce, a board member of Aldeyra Therapeutics, notified the company on April 20, 2026, that he will not stand
8-K — Impact 2/10
Mar 27, 2026
Insider
Brady Todd C sold 1,880,510 shares
President and CEO @ $0.00 ($0.00)
Mar 27, 2026
Insider
Brady Todd C sold 632,318 shares
President and CEO @ $0.00 ($0.00)
Mar 20, 2026
SEC
Two corporate insiders at Aldeyra Therapeutics purchased shares in the open market within a 7-day window, totaling $105,
CLUSTER — Impact 5/10
Mar 19, 2026
Insider
DOUGLAS RICHARD bought 70,000 shares
Director @ $1.40 ($98.0K)
Inst.
MORGAN STANLEY — TRIM
657,032 shares ($3.4M)
Price Targets
$7.60
+398.4% upside
Strong Buy
Current $1.53
Low $2.00
Median $9.00
High $13.00
5 analysts
$2.00
$13.00
Analyst Ratings
5Strong Buy
5Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 18, 2026 | HC Wainwright & Co. | DOWNGRADE | Buy → Neutral |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.09 ▲ +32.9% | $-0.11 — $-0.06 | 47% YoY | 2 |
| Next Q | $-0.07 ▲ +32.3% | $-0.08 — $-0.06 | 46% YoY | 2 |
| Current FY | $-0.34 ▲ +14.9% | $-0.43 — $-0.23 | 39% YoY | 3 |
| Next FY | $-0.20 ▲ +22.3% | $-0.24 — $-0.10 | 42% YoY | 4 |
Latest Reports
NEUTRAL
DEFA14A
2/10
Aldeyra Therapeutics filed additional definitive proxy materials for its 2026 Annual Meeting of Stockholders, scheduled
Apr 27, 2026
NEUTRAL
8-K
2/10
Martin J. Joyce, a board member of Aldeyra Therapeutics, notified the company on April 20, 2026, that he will not stand
Apr 20, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $19.2M | — |
| MORGAN STANLEY | $3.4M | TRIM |
| BANK OF AMERICA CORP | $2.1M | DOUBLED |
| WELLS FARGO & COMPANY/MN | $1.9M | — |
| RENAISSANCE TECHNOLOGIES LLC | $1.8M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Mar 27, 2026 | Brady Todd | A | $0.00 |
| Mar 27, 2026 | Brady Todd | A | $0.00 |
| Mar 19, 2026 | DOUGLAS RICHARD | BUY | $98.0K |
| Mar 18, 2026 | Alfieri Michael | BUY | $7.1K |
Reddit Sentiment
63°
Warm
Bearish
Neutral
Bullish
8 institutional holders with $30.7M total value (5,932,027 shares) as of 2025-Q4. Top holders: VANGUARD, MORGAN, BANK.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 3,698,682 | $19.2M | 62.4% | — |
| 2 | MORGAN STANLEY | 657,032 | $3.4M | 11.1% | TRIM -39.4% |
| 3 | BANK OF AMERICA CORP /DE/ | 410,028 | $2.1M | 6.9% | DOUBLED +590.5% |
| 4 | WELLS FARGO & COMPANY/MN | 369,169 | $1.9M | 6.2% | — |
| 5 | RENAISSANCE TECHNOLOGIES LLC | 350,000 | $1.8M | 5.9% | ADD +77.4% |
| 6 | TWO SIGMA INVESTMENTS, LP | 287,364 | $1.5M | 4.8% | DOUBLED +389.9% |
| 7 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 152,787 | $791.4K | 2.6% | NEW |
| 8 | FMR LLC | 6,965 | $36.1K | 0.1% | TRIM -35.7% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | TRIM | 1,083,319 | 657,032 | -39.4% | $3.4M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 197,300 | 350,000 | +77.4% | $1.8M | 2025-Q4 |
| MORGAN STANLEY | ADD | 775,036 | 1,083,319 | +39.8% | $5.7M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 56,491 | 390,078 | +590.5% | $2.0M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 55,739 | 273,054 | +389.9% | $1.4M | 2025-Q3 |
| UBS Group AG | ADD | 107,253 | 200,739 | +87.2% | $1.0M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 112,800 | 197,300 | +74.9% | $1.0M | 2025-Q3 |
| MORGAN STANLEY | ADD | 555,059 | 775,036 | +39.6% | $3.0M | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 408,542 | 56,491 | -86.2% | $216.4K | 2025-Q2 |
| FMR LLC | TRIM | 10,233 | 6,582 | -35.7% | $25.2K | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 167,100 | 116,600 | -30.2% | $670.5K | 2025-Q1 |
| CITADEL ADVISORS LLC | TRIM | 234,742 | 99,100 | -57.8% | $569.8K | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 131,410 | 55,327 | -57.9% | $318.1K | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 107,400 | 167,100 | +55.6% | $833.8K | 2024-Q4 |
| UBS Group AG | DOUBLED | 26,529 | 94,275 | +255.4% | $470.4K | 2024-Q4 |
| MORGAN STANLEY | ADD | 311,404 | 520,646 | +67.2% | $2.8M | 2024-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 136,733 | — | $737.0K | 2024-Q3 |
3 unique insiders with 2 transactions. Net insider value: $105.1K ($105.1K bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Mar 27, 2026 | Brady Todd C | President and CEO | A | 1,880,510 | $0.00 | $0.00 |
| Mar 27, 2026 | Brady Todd C | President and CEO | A | 632,318 | $0.00 | $0.00 |
| Mar 19, 2026 | DOUGLAS RICHARD | Director | BUY | 70,000 | $1.40 | $98.0K |
| Mar 18, 2026 | Alfieri Michael | Principal Financial Officer | BUY | 5,000 | $1.42 | $7.1K |
3 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 2 neutral. Avg impact: 3.0/10.
NEUTRAL
DEFA14A
2/10
Aldeyra Therapeutics filed additional definitive proxy materials for its 2026 Annual Meeting of Stoc
Apr 27, 2026
NEUTRAL
8-K
2/10
Martin J. Joyce, a board member of Aldeyra Therapeutics, notified the company on April 20, 2026, tha
Apr 20, 2026
BULLISH
CLUSTER
5/10
Two corporate insiders at Aldeyra Therapeutics purchased shares in the open market within a 7-day wi
Mar 20, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (83% buy). Based on 12 analysts: 5 strong buy, 5 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$7.60 mean target
+398.4% upside
Strong Buy (1.60)
$2.00 Low
$13.00 High
| Metric | Value |
|---|---|
| Current Price | $1.53 |
| Target Low | $2.00 |
| Target Mean | $7.60 |
| Target Median | $9.00 |
| Target High | $13.00 |
| # Analysts | 5 |
| Recommendation | Strong Buy (1.60) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.09 | $-0.11 | $-0.06 | 46.9% | +32.9% | — | $0.0B | 0.0% | 2 |
| Next Q 2026-09-30 |
$-0.07 | $-0.08 | $-0.06 | 46.2% | +32.3% | 1↑ 0↓ | $0.0B | 0.0% | 2 |
| Current FY 2026-12-31 |
$-0.34 | $-0.43 | $-0.23 | 38.7% | +14.9% | — | $0.0B | 0.0% | 3 |
| Next FY 2027-12-31 |
$-0.20 | $-0.24 | $-0.10 | 41.8% | +22.3% | 1↑ 0↓ | $0.0B | 558.3% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.085 | |
| 7d ago | $-0.127 | +0.042 |
| 30d ago | $-0.127 | +0.042 |
| 60d ago | $0.630 | -0.715 |
| 90d ago | $-0.150 | +0.065 |
1 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 18, 2026 | HC Wainwright & Co. | DOWNGRADE | Buy | Neutral |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 5 | 5 | 2 | 0 | 0 | 83% | |
| Apr 1, 2026 | 5 | 5 | 2 | 0 | 0 | 83% | |
| Mar 1, 2026 | 5 | 6 | 1 | 0 | 0 | 92% | |
| Feb 1, 2026 | 5 | 6 | 1 | 0 | 0 | 92% | |
| Jan 1, 2026 | 5 | 6 | 1 | 0 | 0 | 92% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
63°
Warm
Bearish
Neutral
Bullish
4 mentions
2 bullish
0 bearish
4 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Mar 19, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 19, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 14, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| Mar 14, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
May 14, 2026
Clinical Trial
The INVIGORATE 2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis
Phase Phase 3 — COMPLETED
Apr 24, 2026
short_volume
Short Volume: ALDX — 55.3% short (0.4M / 0.8M)
Short: 419,988 | Exempt: 4,000 | TRF Vol: 759,958 | Short Ratio: 55.3% | Off-exchange volume (dark pool + OTC)
Apr 23, 2026
Clinical Trial
A Study in Subjects With Retinitis Pigmentosa
Phase Phase 2 — COMPLETED
Apr 23, 2026
short_volume
Short Volume: ALDX — 60.4% short (0.4M / 0.6M)
Short: 384,900 | Exempt: 232 | TRF Vol: 637,393 | Short Ratio: 60.4% | Off-exchange volume (dark pool + OTC)
Apr 22, 2026
short_volume
Short Volume: ALDX — 56.4% short (0.3M / 0.5M)
Short: 306,859 | Exempt: 5,000 | TRF Vol: 543,990 | Short Ratio: 56.4% | Off-exchange volume (dark pool + OTC)
Apr 21, 2026
short_volume
Short Volume: ALDX — 67.8% short (0.5M / 0.7M)
Short: 504,939 | Exempt: 3,412 | TRF Vol: 744,208 | Short Ratio: 67.8% | Off-exchange volume (dark pool + OTC)
Apr 16, 2026
short_volume
Short Volume: ALDX — 57.7% short (0.4M / 0.7M)
Short: 429,403 | Exempt: 3,154 | TRF Vol: 743,717 | Short Ratio: 57.7% | Off-exchange volume (dark pool + OTC)
Mar 18, 2026
short_interest
FTD: ALDX — 1,839,087 shares ($2.3M) failed to deliver
Settlement: 20260318, Price: $1.24, FTD Value: $2,280,467.88, ALDEYRA THERAPEUTICS, INC. COM
Mar 16, 2026
fda_pdufa
PDUFA: ALDX — Reproxalap in dry eye disease — 2026-03-16
FDA target action date 2026-03-16 for ALDX (Aldeyra Therapeutics, Inc.). Drug: Reproxalap. Indication: dry eye disease. FDA extended the PDUFA target
Feb 26, 2026
earnings_calendar
ALDX Q4 2025 Earnings After Market Close — 2026-02-26
Dec 16, 2025
fda_pdufa
PDUFA: ALDX — reproxalap in dry eye disease — 2025-12-16
FDA target action date 2025-12-16 for ALDX (Aldeyra Therapeutics, Inc.). Drug: reproxalap. Indication: dry eye disease. PDUFA target action date for r